Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analyst
Novavax, fashionably late to the COVID-19 vaccine party, could still [...]
Novavax, fashionably late to the COVID-19 vaccine party, could still [...]
Gilead targets 400 jobs, assembles cell therapy manufacturing troika with [...]
Johnson & Johnson, after weak quarter of vaccine sales, will [...]
Gilead, after setbacks, aims to pull a third of its [...]
Johnson & Johnson inks $99M opioid settlement with West Virginia: [...]
Lawmakers blast McKinsey for ‘serious conflict of interest’ in opioid [...]
Bristol Myers settles HIV antitrust suit, but J&J, Gilead still [...]
Poor countries reject COVID vaccines from AstraZeneca because of shorter [...]
Fierce Pharma Asia—Daiichi loses Seagen patent suit; CDMO builds $500M [...]
AstraZeneca tees off new campaign with pro golfer Jason Day [...]